SciSparc Subsidiary NeuroThera Labs Acquires Majority Stake in CliniQuantum
SPRC is trading near its 52-week low of $4.159 (15% above the low) on light trading volume (0.2× avg).
Summary
NeuroThera Labs, a subsidiary of SciSparc Ltd., has signed a definitive agreement to acquire a majority stake in CliniQuantum. This strategic acquisition represents an expansion for SciSparc, potentially enhancing its product pipeline or market reach. For a micro-cap company like SciSparc, any significant M&A activity, even through a subsidiary, is a material event that could impact future growth prospects and financial performance. This news follows the company's recent 1-for-9 reverse share split on March 4, 2026, indicating ongoing corporate activity. Investors will be watching for further details on the financial terms of the acquisition and the strategic rationale.
At the time of this announcement, SPRC was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $4.16 to $97.34. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.